Vecoy, Enzootic team to fight crustacean viruses

Vecoy will deploy its nano-scale virus traps with Enzootic's crustacean aquaculture technologies.

Vecoy Nanomedicines Ltd. and Enzootic Ltd. have signed a commercial cooperation agreement under which Vecoy will deploy its nano-scale virus traps in aquaculture in exchange for royalties from Enzootic if the product reaches market.

Vecoy has developed a proprietary method for killing viruses - a piece of DNA that traps viruses by imitating a cell, which the virus penetrates to reproduce, but where it is trapped, and cannot reproduce or reenter the bloodstream.

The product is under development for use in humans, but Enzootic approached Vecoy to jointly develop the nano-traps to fight crustacean viruses. Enzootic has developed innovative methods for increasing aquaculture yields, with an emphasis on crustacean aquaculture, which account for 10% of total acquaculture produce. Enzootic has several technologies for boosting aquaculture yields, and is adding a medical tool acquired from a company developing treatments for human diseases to its product line.

The global aquaculture industry produces more than 60 million tons a year of products, including fish, shrimps, clams, and seaweed, worth $130 billion a year. Viral outbreaks have cost the industry tens of billions of dollars in recent decades.

Published by Globes [online], Israel business news - www.globes-online.com - on September 16, 2013

© Copyright of Globes Publisher Itonut (1983) Ltd. 2013

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2016